UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
UroGen Pharma (Nasdaq: URGN), a biotech company focused on urothelial and specialty cancer treatments, has scheduled its fourth quarter and full-year 2024 financial results announcement for Monday, March 10, 2025, before market open.
The company will host a live audio webcast and conference call at 10:00 AM Eastern Time on the same day. Investors can access the webcast through UroGen's Investor Relations website, where a replay will be available for approximately 30 days following the presentation.
UroGen Pharma (Nasdaq: URGN), una società biotech focalizzata su trattamenti per il cancro uroteliale e specializzato, ha programmato l'annuncio dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per lunedì 10 marzo 2025, prima dell'apertura del mercato.
La società ospiterà un webcast audio dal vivo e una conference call alle 10:00 AM Eastern Time lo stesso giorno. Gli investitori possono accedere al webcast tramite il sito web delle Relazioni con gli Investitori di UroGen, dove sarà disponibile una registrazione per circa 30 giorni dopo la presentazione.
UroGen Pharma (Nasdaq: URGN), una empresa biotecnológica centrada en tratamientos para el cáncer urotelial y especializado, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024 para el lunes 10 de marzo de 2025, antes de la apertura del mercado.
La empresa llevará a cabo un webcast de audio en vivo y una conferencia telefónica a las 10:00 AM hora del Este el mismo día. Los inversores pueden acceder al webcast a través del sitio web de Relaciones con Inversores de UroGen, donde estará disponible una repetición durante aproximadamente 30 días después de la presentación.
UroGen Pharma (Nasdaq: URGN), 비뇨세포 및 전문 암 치료에 중점을 둔 생명공학 회사는 2024년 4분기 및 연간 재무 결과 발표를 2025년 3월 10일 월요일, 시장 개장 전에 예정하고 있습니다.
회사는 같은 날 동부 표준시 오전 10:00에 라이브 오디오 웹캐스트 및 컨퍼런스 콜을 개최할 것입니다. 투자자들은 UroGen의 투자자 관계 웹사이트를 통해 웹캐스트에 접속할 수 있으며, 발표 후 약 30일 동안 재생이 가능합니다.
UroGen Pharma (Nasdaq: URGN), une société biopharmaceutique axée sur les traitements du cancer urotélial et spécialisé, a programmé l'annonce de ses résultats financiers du quatrième trimestre et de l'année complète 2024 pour le lundi 10 mars 2025, avant l'ouverture du marché.
La société organisera un webinaire audio en direct et une conférence téléphonique à 10h00, heure de l'Est le même jour. Les investisseurs peuvent accéder au webinaire via le site des relations investisseurs d'UroGen, où un enregistrement sera disponible pendant environ 30 jours après la présentation.
UroGen Pharma (Nasdaq: URGN), ein Biotech-Unternehmen, das sich auf uroteliale und spezialisierte Krebsbehandlungen konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Montag, den 10. März 2025, vor Markteröffnung angesetzt.
Das Unternehmen wird am selben Tag um 10:00 Uhr Eastern Time ein Live-Audio-Webcast und eine Telefonkonferenz veranstalten. Investoren können über die Investor-Relations-Website von UroGen auf den Webcast zugreifen, wo eine Wiederholung etwa 30 Tage nach der Präsentation verfügbar sein wird.
- None.
- None.
Conference Call and Webcast Scheduled for Monday, March 10, 2025, at 10:00 AM ET
A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel® reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227186280/en/
INVESTORS:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093
MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3583 ext. 1083
Source: UroGen Pharma Ltd.
FAQ
When will UroGen Pharma (URGN) release its Q4 and full-year 2024 earnings?
What time is UroGen Pharma's (URGN) Q4 2024 earnings call?
How can investors access UroGen Pharma's (URGN) Q4 2024 earnings call?
How long will the replay of URGN's Q4 2024 earnings call be available?
